Skip to main content
Fig. 3 | Molecular Cancer

Fig. 3

From: METTL3/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N6-methyladenosine modification of PD-L1 mRNA in breast cancer

Fig. 3

IGF2BP3 mediates PD-L1 mRNA expression in an m6A-dependent manner. a-c PD-L1 mRNA, protein and cell surface expression levels were tested by qRT-PCR, western blot and flow cytometry in sh-ctrl or sh-IGF2BP3 MDA-MB-231 and HCC38 cells. d-e The interaction between IGF2BP3 and PD-L1 mRNA was analyzed by RIP-qPCR assay with overexpression or knockdown of IGF2BP3. f The binding of IGF2BP3 was tested by RIP-qPCR in sh-METTL3 and control cells. g PD-L1 mRNA levels were analyzed by qRT-PCR assay in MDA-MB-231 and HCC38 cells after actinomycin D treatment. Results were presented as mean ± SD of three independent experiments. *p < 0.05; **p < 0.01; ***p < 0.001

Back to article page